Analysts think ASMB stock price could increase by 50%
Jan 07, 2026, 12:25 PM
-10.23%
What does ASMB do
Assembly Biosciences, a biotechnology company based in South San Francisco, develops treatments for chronic hepatitis B and other infectious diseases, with a pipeline including multiple antiviral agents. The company, which went public in December 2010, employs 65 people.
6 analysts think ASMB stock price will increase by 50.00%. The current median analyst target is $45.90 compared to a current stock price of $30.60. The lowest analysts target is $39.39 and the highest analyst target is $65.10.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.